Sonoma Pharmaceuticals Inc., of Petaluma, Calif., received two new regulatory approvals from the United Arab Emirates Ministry of Health & Prevention. The first approval, for Pediacyn Hydrogel (hypochlorous acid), is intended for treatment of atopic dermatitis and other dermatoses forming a protective barrier against physical, chemical and microbial invasion of the atopic dermatitis lesions under the supervision of a health care professional. The second, for Epicyn Scar Hydrogel (hypochlorous acid), also under the supervision of a health care professional, is intended for the management of scars by forming a protective barrier against physical, chemical and microbial invasion of the scar.